lead molecule

lead molecule

(lēd)
A chemical compound thought to be useful, safe, and distinctive enough that it might prove to be a good candidate for drug development.
References in periodicals archive ?
Proceeds will be used to initiate a phase 1 clinical study for the company's lead molecule, APX3330, a novel first-in-class oral treatment for patients with cancer.
The funds will go towards further developing multiple drug candidates, including Bicycle's lead molecule, BT1718, a first-in-class drug for cancers of high unmet need.
Identification of the lead molecule is currently in progress.
These all molecules are purchasable, so, any lead molecule can be purchased and are delivered within a period of up to 10 weeks depending upon the availability.
The target firma[euro](tm)s lead molecule, COR-1, is a small cyclic peptide presently in early clinical development for the treatment of heart failure.
Cerecor, which develops prescription medicines whose main activity is in the human nervous system, said the financing was a key step in the commercialisation effort for its lead molecule FP01 for chronic and acute cough.
The researchers say that their lead molecule is effective in promoting survival in three different hES cell lines and that their findings emphasize the critical importance of the ROCK2/PRK2 signalling pathway in human embryonic cell survival.
Given the recently achieved synthesis of sceptrin in multi-gram quantities by the Baran laboratory, sceptrin could prove to be an attractive lead molecule for further preclinical testing and development for therapeutic purposes," said Dr.
TRIN 2755, the company's lead molecule in a series of novel triazene analogs, exerts rapid metabolic clearance while, at the same time, showing very good tolerability in early toxicology studies.
Researchers regard this as a new finding for carvacrol and suggest that with this evidence and with ongoing research, carvacrol may emerge as a lead molecule with its cardioselective calcium channel blocking properties.
The company's first Phase I clinical trial for its lead molecule, trans sodium crocetinate, shows the drug is well-tolerated in healthy human subjects at doses significantly higher than the estimated efficacious human dose.
Under the agreement, Diosynth Biotechnology will support the process improvement, process development and clinical product manufacturing for the lead molecule.